Glycerylnitrat

Glycerylnitrat is a prescription medication that contains the active ingredient glyceryl trinitrate, provided as an intravenous solution intended for hospital use. It belongs to the nitrate vasodilator class and is marketed in the European Union. The product is supplied without a specific brand name and is administered by healthcare professionals under medical supervision to manage acute cardiovascular conditions and to relieve symptoms associated with reduced myocardial oxygen supply.

Glycerylnitrat is indicated for the rapid relief of chest pain and for the management of several acute cardiovascular emergencies. It is administered intravenously in controlled clinical settings.

- Acute angina pectoris unresponsive to oral nitrates. - Acute decompensated heart failure with pulmonary congestion. - Hypertensive emergencies requiring immediate blood pressure reduction. - Peri‑operative myocardial ischemia prophylaxis. - Severe coronary artery spasm (Prinzmetal angina).

The safety profile of Glycerylnitrat includes both frequently observed and less common adverse reactions, which are generally related to its vasodilatory action.

Common: - Headache, often described as throbbing. - Flushing or warmth of the face and neck. - Hypotension leading to dizziness. - Tachycardia or reflex heart rate increase. - Nausea or mild vomiting.

Serious: - Severe hypotension causing syncope. - Methemoglobinemia, a rare blood disorder. - Acute myocardial infarction in susceptible patients. - Life‑threatening arrhythmias. - Severe allergic reactions such as anaphylaxis.

Before using Glycerylnitrat, clinicians should assess patient history and monitor vital signs closely during therapy.

- Avoid use in patients with known hypersensitivity to nitrates. - Use cautiously in patients with severe anemia or increased intracranial pressure. - Monitor blood pressure continuously to detect excessive drops. - Assess for concurrent use of phosphodiesterase‑5 inhibitors, which can amplify hypotensive effects. - Adjust dosage in patients with hepatic or renal impairment. - Educate patients about the risk of tolerance with prolonged exposure.

Glycerylnitrat may interact with several drug classes, influencing its efficacy and safety.

Avoid: - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) due to risk of profound hypotension. - Other potent vasodilators such as hydralazine or other nitrates, which can cause additive blood pressure lowering. - Certain antihypertensive agents (e.g., ACE inhibitors, beta‑blockers) when combined may require close monitoring.

Use with caution: - Diuretics, especially loop diuretics, which may exacerbate volume depletion. - Alcohol, which can enhance vasodilatory effects. - Anticoagulants, as hypotension may increase bleeding risk. - Drugs that affect hepatic metabolism (e.g., CYP3A4 inhibitors) may alter nitrate clearance.